Skip to content

Clinical trials

Observational Opioid-Related Disorders trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Opioid-Related Disorders Phase: Observational Country / region: United States Clear all

122 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20032
20057
20062
20072
20083
20092
20103
20112
20121
20131
20144
20153
20165
20174
201810
201913
20209
20217
20224
202310
20247
202510
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed78
Recruiting19
Unknown status7
Terminated5
Active, not recruiting4
Not yet recruiting3
Enrolling by invitation3
Withdrawn2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Yale University11
Wayne State University8
National Institute on Drug Abuse (NIDA)6
Indivior Inc.5
University of Pittsburgh5
NYU Langone Health4
Boston Medical Center3
Senthil Sadhasivam3
University of California, Los Angeles3
Cambridge Health Alliance2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Opioid-Related Disorders122
Substance-Related Disorders24
Alcoholism9
Heroin Dependence9
Narcotic-Related Disorders7
Cocaine-Related Disorders6
HIV Infections6
Opiate Overdose5
Postoperative Pain5
Neonatal Abstinence Syndrome4

Trials

Showing 1 to 25 of 122. Each trial links to its page on Pharma Observatory.

22 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.